Affiliation:
1. Gilead Sciences, Foster City, California, USA
Abstract
In clinical studies GS-US-380-1489 (study 1489) and GS-US-380-1490 (study 1490), bictegravir-emtricitabine-tenofovir alafenamide (B-F-TAF), dolutegravir-abacavir-lamivudine (DTG-ABC-3TC), and dolutegravir plus emtricitabine-tenofovir alafenamide (DTG+F-TAF) treatment achieved high rates of virologic suppression in HIV-1 treatment-naive participants through week 48. Preexisting primary drug resistance was present at levels of 1.3% integrase strand transfer inhibitor resistance (INSTI-R), 2.7% nucleoside reverse transcriptase inhibitor resistance (NRTI-R), 14.1% nonnucleoside reverse transcriptase inhibitor resistance (NNRTI-R), and 3.5% protease inhibitor resistance (PI-R) in the 1,274 participants from these studies.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference33 articles.
1. Panel on Antiretroviral Guidelines for Adults and Adolescents. 2018. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services, Washington, DC.
2. European AIDS Clinical Society (EACS). 2017. Guidelines, version 9.0. (English). European AIDS Clinical Society, London, United Kingdom.
3. Gilead Sciences, Inc. 2018. BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide) tablets, for oral use, package insert. Gilead Sciences, Inc., Foster City, CA.
4. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile
5. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献